Several other analysts have also issued reports on the stock. Northland Securities reiterated a buy rating and issued a $10.00 target price on shares of pSivida in a research note on Monday, December 11th. ValuEngine lowered shares of pSivida from a sell rating to a strong sell rating in a research note on Friday, December 1st. HC Wainwright reiterated a buy rating and issued a $5.00 target price on shares of pSivida in a research note on Wednesday, November 8th. Finally, Laidlaw began coverage on shares of pSivida in a research note on Wednesday, November 8th. They issued a buy rating and a $5.00 target price for the company. One investment analyst has rated the stock with a sell rating and seven have issued a buy rating to the company. pSivida currently has an average rating of Buy and an average target price of $7.57.
Shares of pSivida (NASDAQ PSDV) opened at $1.08 on Friday. pSivida has a one year low of $1.02 and a one year high of $2.45.
A hedge fund recently bought a new stake in pSivida stock. OxFORD Asset Management LLP purchased a new stake in shares of pSivida Corp. (NASDAQ:PSDV) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 69,004 shares of the company’s stock, valued at approximately $118,000. OxFORD Asset Management LLP owned 0.18% of pSivida as of its most recent filing with the Securities & Exchange Commission. 9.70% of the stock is owned by hedge funds and other institutional investors.
pSivida Corp. develops drug delivery products primarily for the treatment of chronic eye diseases. The Company operates through the biotechnology sector segment. The Company has developed three products for treatment of back-of-the-eye diseases, which include Medidur for posterior segment uveitis, its lead product candidate that is in pivotal Phase III clinical trials; ILUVIEN for diabetic macular edema (DME), its lead licensed product that is sold in the United States and European Union (EU) countries, and Retisert.
Receive News & Ratings for pSivida Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for pSivida and related companies with MarketBeat.com's FREE daily email newsletter.